Clinical Trials
4 trialsNCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT02926638 2020-03-19
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
SWOG Cancer Research Network
Phase 2/3 Terminated
NCT02137343 2016-04-04
RILOMET-2
Amgen
Phase 3 Terminated
NCT01697072 2016-02-09
RILOMET-1
Amgen
Phase 3 Terminated